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Summary Objectives Danusertib is a serine/threonine
kinase inhibitor of multiple kinases, including aurora-A,
B, and C. This explorative study aims to identify possible
relationships between single nucleotide polymorphisms in
genes coding for drug metabolizing enzymes and transporter
proteins and clearance of danusertib, to clarify the interpatient
variability in exposure. In addition, this study explores the
relationship between target receptor polymorphisms and
toxicity of danusertib. Methods For associations with
clearance, 48 cancer patients treated in a phase I study were
analyzed for ABCB1, ABCG2 and FMO3 polymorphisms.
Association analyses between neutropenia and drug target
receptors, including KDR, RET, FLT3, FLT4, AURKB and
AURKA, were performed in 30 patients treated at recom-
mended phase II dose-levels in three danusertib phase I or
phase II trials. Results No relationships between danusertib
clearance and drug metabolizing enzymes and transporter
protein polymorphisms were found. Only, for the one patient
with FMO3 18281AA polymorphism, a significantly higher
clearance was noticed, compared to patients carrying at
least 1 wild type allele. No effect of target receptor
genotypes or haplotypes on neutropenia was observed.
Conclusions As we did not find any major correlations
between pharmacogenetic variability in the studied
enzymes and transporters and pharmacokinetics nor
toxicity, it is unlikely that danusertib is highly susceptible
for pharmacogenetic variation. Therefore, no dosing
alterations of danusertib are expected in the future, based
on the polymorphisms studied. However, the relationship
between FMO3 polymorphisms and clearance of danusertib
warrants further research, as we could study only a small
group of patients.
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Introduction
Aurora kinases are serine/threonine kinases with a key role
in mitosis [1–9]. Danusertib (PHA-739358) is a new active
moiety in cancer treatment which selectively inhibits the
ATP site of aurora-A (AURKA, IC50 = 13 nM), aurora-B
(AURKB, IC50=79 nM) and aurora-C (AURKC, IC50=
61 nM) kinases [10, 11]. Inhibition of aurora-A or aurora-B
activity in tumor cells results in impaired chromosome
alignment, weakening of the mitotic checkpoint, polyploidy,
and subsequent cell death [12, 13]. Danusertib shows
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DOI 10.1007/s10637-010-9405-7anti-tumor activity in a wide range of cancer cell lines and
xenograft tumor models [14]. Tested in a panel of 32
kinases, danusertib also showed increased affinity for
multiple other kinases (IC50 <0.50 µM), including ret
proto-oncogene (RET), vascular endothelial growth factor
receptor 3 (FLT4, VEGFR3), and fms-related tyrosine kinase
3 (FLT3). Therefore, inhibition of these kinases may
influence danusertib efficacy or toxicity in cancer patients.
The major route of metabolism of danusertib involves
the formation of the N-oxide metabolite, mainly through the
enzyme flavin containing monooxygenase 3 (FMO3),
forming an inactive metabolite. Furthermore, danusertib
was found to be a substrate for efflux proteins ATP-binding
cassette B1 (ABCB1/MDR1) and G2 (ABCG2/BCRP in in
vitro studies (unpublished data). In addition, it has been
shown that histone H3 is phosphorylated by aurora-B and
phosphorylation of histone H3 is inhibited in skin, bone
marrow and xenograft tumors after treatment with
danusertib [15]. As a consequence, the extent of histone
H3 phosphorylation is studied as a pharmacodynamic
biomarker of danusertib effectiveness.
Recently, this new compound has been introduced in
human research. In a phase I study, performed at the Leiden
University Medical Center, Leiden and the Erasmus
University Medical Center, Rotterdam (The Netherlands),
the pharmacokinetics of danusertib were characterized by
relatively low to moderate plasma clearances (range 10–59
L/hour) and an elimination half-life of about 30 h [16].
Danusertib showed linear pharmacokinetics over the
dose-range studied. At all dose levels, the inter-patient
variability of the primary pharmacokinetic parameters of
danusertib was remarkably high, with a coefficient of
variation of 40–50%, which is in line with other anti-cancer
drugs. Toxicity increased with danusertib dose. However,
currently it is unclear whether pharmacogenetic variability in
drug metabolizing or transporting proteins can explain a large
part of the inter-individual variability in pharmacokinetics
and/or toxicity-profile. Therefore, the current explorative
study aims to identify possible (and clinically relevant)
relationships between single-nucleotide polymorphisms
(SNPs) in genes coding for drug metabolizing enzymes and
for transporter proteins and pharmacokinetic parameters of
danusertib. In this study we also explore the possible
relationship between polymorphisms in genes encoding the
drug target receptors and toxicity of danusertib.
Methods
This study was conducted on patients treated with danusertib
in 3 studies, one phase I and two phase II studies.
Descriptions of the study population and treatment regimens
are given in the patients and samples paragraph below.
Residual blood samples for pharmacogenetic analyses to
compare with pharmacokinetics were available for all
patients treated in the phase I study. For association analyses
with toxicity, all patients treated at the recommended phase
II dose (RP2D), in both the phase I and phase II studies,
were included.
Patients and samples
Eligibility criteria, drug administration procedures, safety,
pharmacokinetic and efficacy methods as used in the phase
I trial are described in detail elsewhere [17].
Briefly, Group A patients had histologically or cytolog-
ically confirmed advanced or metastatic solid tumors for
whom no standard therapy was available, with an Eastern
Cooperative Oncology Group (ECOG) performance status
≤1. Danusertib was administered intravenously on days 1,
8, 15 every 28 days. Doses were escalated from 45 mg/m
2
to 400 mg/m
2 in the 6-hour infusion schedule, and from
250 mg/m
2 to 330 mg/m
2 in the subsequent 3-hour infusion
schedule. The trial had a standard 3+3 phase I dose
escalation study design. In the phase II study from which
group B patients were entered, men with metastatic
hormone refractory prostate cancer, progressive after
docetaxel treatment were eligible. Patients of group B
were randomized between treatment with 330 mg/m
2 of
danusertib on days 1, 8, 15 every 28 days in a 6-hour
infusion schedule or with 500 mg/m
2 of danusertib on
days 1 and 15 every 28 days in 24-hour infusion schedule
according to the phase II study protocol. The total
exposure in both groups is expected to be identical, and
in line with the RP2D as determined in phase I studies
[8, 18]. For group C, patients with several tumor types
(see Table 1), progressive after 1 or 2 lines of chemotherapy
dependingontumortypewereeligible.Treatmentconsisted
of 500 mg/m
2 of danusertib on days 1 and 15 every
28 days in 24-hour infusion schedule. No pharmacokinetic
analyses were performed in the phase II trials.
For all groups, patients were evaluated for adverse
events and toxicity according to the National Cancer
Institute Common Terminology Criteria (NCI-CTC),
version 3.0. Response evaluation was performed every
2 cycles and was assessed according to RECIST 1.0
[19].
Residual blood samples taken for routine patient care
were stored at−20°C at the local hospital laboratories. Of
each patient, one frozen whole blood sample was
collected from the two participating hospitals. All
samples were anonimyzed by a third party, according to
the instructions stated in the Codes for Proper Use and
Proper Conduct (www.federa.org). Approval from the
institutional medical ethical review boards was obtained
prior to analysis.
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Pharmacokinetic (PK) evaluation was performed by
collecting blood samples on days 1 to 4, day 8, days 15
to18 and day 22 of cycle 1, and days 1 and 15 of cycles 2
and 4. Pharmacokinetic evaluation was carried out using a
non-compartmental approach with the aid of WinNonlin
software (version 3.1, Pharsight Inc., Mountain View, CA,
USA). In this study, danusertib clearance (L/hour/m
2)w a s
selected as the pharmacokinetic parameter to associate
with enzyme and transporter genetic polymorphisms. As
mentioned in the phase I report, clearance was not
influenced by duration of infusion and was comparable
in both 3-hour and 6-hour infusion schedules; 16.2 and
Table 1 Patient characteristics, danusertib induced toxicity in the first cycle, and pharmacokinetic/pharmacodynamic results
Baseline characteristics All patients n (%) N=63 Phase I patientsn (%) N=48
a RP2D patients n (%) N=30
b
Gender, male 43 (68) 35 (73) 20 (67)
Race, caucasian 62 (98) 47 (98) 29 (97)
Age, years
Median (range) 58 (22–75) 58 (22–75) 60 (38–74)
Patient Group
A (phase I) 48 (76) 48 (100) 15 (50)
B (phase II, prostate cancer) 7 (11) – 7 (23)
C (phase II, various tumor types) 8 (13) – 8 (27)
RP2D Group
330 mg/m2 d1,8,15 every 4 weeks 20 (31) 15 (31) 20 (67)
500 mg/m2 d 1 and 15 every 4 weeks 10 (16) – 10 (33)
Tumor type
Colorectal cancer 19 (30) 18 (38) 10 (33)
Breast cancer 6 (10) 1 (2) 5 (17)
Esophageal cancer 4 (6) 4 (8) 2 (7)
Ovarian cancer 3 (5) 2 (4) 1 (3)
Pancreatic cancer 4 (6) 3 (6) 1 (3)
Prostate cancer 8 (13) 1 (2) 7 (23)
Miscellaneous 19 (30) 19 (39) 4 (13)
ECOG performance score
0 15 (24) 8 (17) 11 (37)
1 48 (76) 40 (83) 19 (63)
Nr of previous treatment lines
Median (range) 3 (0–12) 3 (0–12) 3 (1–7)
Toxicity during cycle 1
Any toxicity grade 1–4 51 (81) 37 (77) 28 (93)
Any toxicity grade 3 or 4 22 (35) 15 (31) 15 (50)
Neutropenia grade 1–4 34 (54) 25 (52) 19 (63)
Neutropenia grade 3 or 4 18 (29) 12 (25) 13 (43)
Febrile neutropenia 1 (2) 1 (2) 1 (3)
Clearance day 1 cycle 1 (L/hour/m
2), n=47
Median±SD n.a. 17.8±5.8 n.a.
Histone H3 phosphorylation, n=28, Δ%
Median±SD n.a. -92.3 ± 13.1 n.a.
Number of treatment courses
Median (range) 2 (1–31) 2 (1–31) 2 (1–15)
RP2D Recommended phase 2 dose, ECOG Eastern Cooperative Oncology Group,SD standard deviation, Histone H3 phosphorylation:% change
in number of positive cells by immunohistochemistry for Histone H3 phosphorylation
aOne patient included in toxicity analyses, but no PK data available
bFifteen patients of the phase I trial were treated at the RP2D level
Invest New Drugs (2011) 29:953–962 95518.0 L/hour/m
2 respectively [20]. Clearances in our study
were also comparable to mean danusertib clearance
reported in another phase I study using even a 24-hour
infusion schedule [8]. Therefore, patients treated at both
3-hour and 6-hour infusion schedules were included in
the pharmacokinetic association analyses.
The most frequent and clinically relevant danusertib
induced side effects, known from phase I trials, are grade 3
and4neutropenia,definedasneutrophilcounts0.5–1.0*10
9/L
and <0.5*10
9/L, respectively, and febrile neutropenia. These
side-effects were therefore considered to be the best
candidate toxicity parameters for the association analyses
with drug target receptor genetic polymorphisms.
For the association analysis with neutropenia, we
included patients treated at the RP2D (thus, 330 mg/m
2
days 1, 8, 15 q4w or 500 mg/m
2 days 1 and 15 q4w
equivalent). Since grade 3–4 neutropenia was associated
with danusertib dose, association analyses were performed
with neutropenia developing in the first cycle only,
excluding the effects of cumulative danusertib dose and
dose reductions in subsequent cycles [21]. The probability
of grade 3 or 4 neutropenia in the first danusertib cycle was
not influenced by infusion duration and this toxicity was
also comparable in both used schedules [8, 22]. Therefore,
for the purpose of analyzing associations between drug
target receptor polymorphisms and neutropenia all
patients treated at the RP2D were combined. Only one
case of febrile neutropenia was observed, and as a result
association analyses with febrile neutropenia could not be
performed.
Skin biopsies for biomarker analysis (Group A) were
performed at baseline, and 10 min before the end of the first
infusion in the first cycle. As a biomarker for aurora-B
inhibition, the inhibition of histone H3 phosphorylation in
the skin was measured by immunohistochemistry [23–25].
Change in histone H3 phosphorylation was used as
parameter for association analyses with polymorphisms in
the aurora-B receptor.
Selection of candidate genes
Candidate genes were selected b a s e do nt h ei n f o r m a t i o no f
preclinical pharmacology studies as reported in the
Investigator’s brochure (Nerviano Medical Sciences on
file). Briefly, histone H3 is phosphorylated by aurora-B
and phosphorylation of histone H3 is inhibited in a
number of different tissues (skin, bone marrow, and
tumor) after treatment with danusertib. As a consequence,
the extent of histone H3 phosphorylation is studied as a
biomarker for danusertib effectiveness. The major route of
metabolism of danusertib involves the formation of the
N-oxide of the N-methyl piperazine moiety, mainly
through the enzyme FMO3. Furthermore, PHA-739358
was found to be a substrate for efflux proteins ABCG2
and ABCB1 in in vitro studies [26]. Therefore, for
association with clearance ABCB1, ABCG2, and FMO3
were the genes selected.
Danusertib selectively inhibits the ATP site of aurora-A
(IC50 = 13 nM), aurora-B (IC50=79 nM) and aurora-C
(IC50=61 nM) kinases. Tested in a panel of 32 kinases,
PHA-739358 also showed increased affinity for other
kinases, including C-ABL, NTRK1, RET, FGFR1, LCK,
FLT4, C-KIT, KDR, CDK2A, STLK1, and FLT. Therefore,
inhibition of these kinases may add to danusertib efficacy
or toxicity in cancer patients [27, 28]. For correlation with
danusertib toxicity selected genes were the drug target
genes encoding AURKA, AURKB, AURKC, C-ABL,
NTRK1, RET, FGFR1, LCK, FLT4, C-KIT, KDR, CDK2A,
STLK1, and FLT3.
The single nucleotide polymorphisms (SNPs) were
selected, taking into consideration one or more of the
following criteria: a validated SNP assay, SNP should
preferably cause non-synonymous amino acid changes, an
indication for clinical relevance should be available from
previous publications, and the preferred minority genotype
allele-frequency should be at least ∼10% in Caucasians. For
ABCB1, ABCG2, FMO3, AURKA, AURKB, RET, FLT4,
KDR, and FLT3, one or multiple SNPs could be selected
according to these criteria.
DNA extraction, SNP analysis, and haploblock selection
DNAwas isolated from EDTA-blood samples with MagNA
Pure Compact DNA Isolation kit (Roche Diagnostics,
Almere, The Netherlands). DNA concentrations were
quantified on the nanodrop (Isogen, IJsselstein, The
Netherlands). From the patients of whom whole blood
samples were unavailable, DNA was isolated from blood-
serum with MagNA Pure Compact DNA Isolation kit.
Taqman assays were obtained from Applied Biosystems
(Applied Biosystems, Nieuwerkerk aan den IJssel, The
Netherlands). SNP genotyping was performed with the
BIOMARK 48.48 dynamic array (Fluidigm Corporation,
South San Francisco, CA, USA). All assays were performed
according to protocols provided by the manufacturer. As a
quality control, 4 samples were genotyped in duplicate for all
assaysand2assaysweretestedinduplicateonallsamples.As
negative controls water was used. Overall, no inconsistencies
in genotypes were observed. To genotype DNA extracted
from blood serum on the Biomark, a pre-amplification step
was necessary. Briefly, to 1.25 μl of serum-DNA a dilution of
all taqman assays in a total volume of 1.25 μl and 2.5 μlo f
pre-amplification mastermix (Applied Biosystems) was
added, and amplified on a conventional PCR machine. This
mixture was 20× diluted and 2.5 μl was used in the Biomark
conform their protocol.
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success rates for all genotyping analyses were 100%, except
for RET 135G>A with 22% invalid results, despite
repeated analyses. Genotype frequencies for 21 of 22
SNPs were in Hardy-Weinberg equilibrium (P>0.05).
KDR 1719A>T (rs1870377) was not in Hardy-Weinberg
equilibrium which was most likely due to the limited
population size. Our genotype frequencies were in line
with previously reports and frequencies for Caucasians, as
reported in the NCBI database (www.ncbi.nlm.nih.gov).
If linkage disequilibrium between SNPs was detected,
haplotypes were set with gPLINK (http://pngu.mgh.
harvard.edu/purcell/plink/) [29]. No phase uncertainty in
the defined haploblocks and haplotypes (Rh^2> 0.98) was
seen. The haploblock for ABCB1 included 1236C>T,
2677G>A/T, and 3435C>T; the haploblock for ABCG2
included 15994G>A, and 1143C>T; and the haploblock for
FMO3 included 15167G>A, 21443A>G, and 18281G>A
(Table 4).
Statistical analysis
Differences in pharmacokinetic and pharmacodynamic
parameters among genotypes were analyzed by the
Student’s t-test, or analysis of variance (ANOVA) for
continuous variables or chi-square test for dichotomous
variables, where appropriate. For toxicity, differences in
genotype distribution were tested by 3×2 cross-tabulations
for each genotype, and by 2×2 cross-tabulations for
carriers versus noncarriers, with analysis by a two-sided
chi-square test. Polymorphisms within a gene were tested
with the chi-square test (P-value<0.05) to detect linkage
disequilibrium. Associations between the number of copies of
a haplotype and clinical parameters were performed using a
chi-square test for dichotomous variables and Student’s t-test,
ANOVA for continuous variables.
All statistical analyses were performed using SPSS 16.0
software (SPSS, Chicago, IL) and were two-sided, with a
level of significance of α=0.05. Because of the explorative
nature of this study, we did not perform a correction for
multiple comparisons.
Results
Baseline patient characteristics, observed treatment-related
toxicities, pharmacokinetics and treatment duration are
presented in Table 1. For associations with clearance, 48
cancer patients treated in the phase I study were analyzed
for ABCB1, ABCG2 and FMO3 polymorphisms. In total, 30
patients at the RP2D were evaluable for pharmacogenetic
analyses to compare with toxicity. Our population com-
prised 98% Caucasians with 68% males and 32% females.
Most frequent tumor types were colorectal cancer (30%),
prostate cancer (13%) and breast cancer (10%). Danusertib
doses used ranged from 45 mg/m
2 to 500 mg/m
2, with
infusion times of 3 (14%), 6 (70%) and 24 h (16%),
according to the designs of the mentioned phase I and
phase II trials.
Haplotype frequencies for ABCB1 were GCC 0.443,
TTT 0.412, GTC 0.096, and GCT 0.024, for ABCG2 CC
0.691, TT 0.230, and TC 0.079, and for FMO3 AGA 0.437,
GGG 0.437, and GAG 0.127. Haploblock for KDR
included−604 T>C, 1192G>A, and 1719A>T, for RET
37412G>A, and 135G>A, and for AURKA 169G>A, and
91A>T. Haplotype frequencies for KDR were TCT 0.410,
CCT 0.316, CCA 0.109, TCA 0.087, CTA 0.047, CTT
0.021, and TTA 0.0114, for RET GG 0.602, and GA 0.938,
and for AURKA GA 0.556, AA 0.222, and GT 0.222.
There was no apparent association between cycle
1 day 1 danusertib clearance (L/hour/m
2) and genetic
polymorphisms in ABCB1 or ABCG2 (Table 3). However,
for FMO3, patients carrying at least one G allele had a
significantly slower clearance compared to the 18281 AA
patients (P=0.017).
No relationship between observed grade 3–4 neutropenia
in the first treatment cycle and KDR, RET, FLT3, FLT4,
Table 2 Genotype frequency results
Gene and Variant No. Patients p
a q
b
ABCB1 1236C>T 63 0.556 0.444
ABCB1 2677G>A/T 63 0.563 0.437
ABCB1 3435C>T 63 0.484 0.516
ABCG2 421C>A 63 0.889 0.111
ABCG2 346G>A 63 0.952 0.048
ABCG2 1143C>T 63 0.770 0.230
ABCG2 15994G>A 63 0.690 0.310
FMO3 15167G>A 63 0.563 0.437
FMO3 21443A>G 63 0.794 0.206
FMO3 18281G>A 63 0.873 0.127
KDR-604T>C 63 0.508 0.492
KDR 1192G>A 63 0.921 0.079
KDR 1719A>T 63 0.254 0.746
KDR 54G>A 63 0.563 0.437
KDR-92G>A 63 0.762 0.238
RET 37412G>A 63 0.810 0.190
RET 135G>A 49 0.776 0.224
FLT3 738C>T 63 0.397 0.603
FLT4 1480A>G 63 0.881 0.119
AURKB 893G>A 63 0.889 0.111
AURKA 169G>A 63 0.778 0.222
AURKA 91A>T 63 0.778 0.222
ap frequency of wild-type allele,
bq frequency of variant allele
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the ABCB1, ABCG2, and FMO3 haplotypes did not show
an association with danusertib clearance, nor did KDR,
RET, AURKA haplotypes relate to danusertib induced grade
3–4 neutropenia (Table 5).
Also, no association was observed between the studied
AURKB polymorphism and change in level of histone H3
phosphorylation induced by danusertib. The decrease in
histone H3 phosphorylation for AURKB homozygous wild
type genotypes (GG) was 91% (SD 13.3%), while the
heterozygous genotype (GA) had a decrease of 84% (SD
12.2%, P=0.223).
Discussion
Aurora kinase inhibitors are relatively new and promising
agents in development for anticancer treatment [1–9]. The
Gene Polymorphism Genotype No. Patients Clearance L/hour/m
2 d1c1
Mean SD
ABCB1 1236C>T CC 16 17.8 6.5
CT 21 18.3 5.9
TT 10 18.6 4.9
P-value 0.930
2677G>A/T GG 17 18.2 6.6
GT 20 18.5 5.8
TT 10 17.7 4.9
P-value 0.948
3435C>T CC 13 19.5 6.1
CT 21 17.7 5.9
TT 13 17.8 5.6
P-value 0.638
ABCG2 421C>A CC 36 18.1 6.1
CA 11 18.8 4.8
P-value 0.621
346G>A GG 45 18.2 5.9
GA 2 18.6 5.2
P-value 0.755
143C>T CC 29 18.9 6.1
CT 15 17.3 5.5
TT 3 16. 3.6
P-value 0.537
15994G>A GG 23 18.5 5.0
GA 21 18.2 6.2
AA 3 16.5 3.6
P-value 0.859
FMO3 15167G>A GG 15 19.5 6.6
GA 20 18.1 6.0
AA 12 16.9 4.2
P-value 0.537
21443A>G AA 27 19.2 6.3
AG 18 16.9 5.1
GG 2 16.4 1.3
P-value 0.382
18281G>A GG 35 18.1 5.2
GA 11 17.2 6.1
AA 1 34.0 n.a.
P-value 0.017
Table 3 Association between
genetic polymorphisms and
danusertib clearance
n.a: not applicable
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and efficacy is still very limited. Danusertib is the first aurora
kinase inhibitor in which a pharmacogenetic pathway
analysis has been performed to clarify pharmacokinetic and
pharmacodynamic features of the drug.
In the last decade, well known examples of anti-cancer
drugs can be given, for which initial recommended dose-
levels had to be changed based on toxicity in subgroups of
patients [30–33]. These subgroups of patients, with in
general decreased enzymatic function based on genetic
polymorphisms, could have been identified earlier if
pharmacogenetic knowledge was available at an earlier
stage. Therefore, it is recognized more and more that
pharmacogenetic research in the earliest stages of
development of new anti-cancer agents is highly relevant.
While the basic characteristics of the new agent have to
become more clear, also selection of patients with
potential increased toxicity, or decreased efficacy, should
be performed as early as possible. Therefore, the decision
was made not to delay the pharmacogenetic analyses till
after registration of the compound, but to explore
potentially clinical relevant pharmacogenetic variation at
this stage of development.
Our study was conducted in patients of a recent phase I
trial and subsets of two phase II trials of danusertib, and
therefore patient numbers for both pharmacokinetic and
Neutropenia grade 3–4 p-value
Gene Polymorphism Genotype Total No. Patients No Yes wt/wt vs wt/m vs m/m
KDR −604T>C TT 6 3 3 0.308
TC 15 7 8
CC 9 7 2
1192G>A GG 27 15 12 1.000
GA 3 2 1
1719A>T AA 1 0 1 0.426
AT 15 8 7
TT 14 9 5
54G>A GG 9 5 4 0.673
GA 16 10 6
AA 5 2 3
−92G>A AA 3 3 0 0.265
AG 7 4 3
GG 20 10 10
RET 37412G>A GG 24 14 10 0.507
GA 5 2 3
AA 1 1 0
135G>A GG 16 9 7 0.489
3 missing GA 8 6 2
AA 3 1 2
FLT3 738C>T CC 5 4 1 0.414
CT 15 7 8
TT 10 6 4
FLT4 1480A>G AA 23 12 11
AG 7 5 2
AURKB 893G>A GG 22 11 11 0.407
GA 8 6 2
AURKA 169G>A GG 18 10 8 0.672
GA 11 6 5
AA 1 1 0
91A>T AA 20 11 9 0.110
AT 6 2 4
TT 4 4 0
Table 4 Association between
genetic polymorphisms and
grade 3–4 neutropenia in cycle 1
in all patients at RP2D levels
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However, in the phase I trial DNA-data were available for
almost the entire patient population, making selection bias
less likely. The two phase II trials are still ongoing and blood
for DNA analysiswas available for all patientsincludedinthe
trialsattheErasmusUniversityMedicalCenteratthemoment
of pharmacogenetic analyses.
A correlation between danusertib pharmacokinetics and
pharmacogenetic variation is only seen for the FMO3
18281G>A homozygous variant and clearance. However,
this is based on a single patient for whom clearance was
markedly elevated. Therefore, the relevance of this finding is
unclear. For the other 2 SNPs (15167 G>A and 21443G>A)
in this gene, a pattern to altered clearance, based on
genotype, is suggested. As FMO3 is responsible for the
main route of metabolism of danusertib, this warrants
further research.
Currently, the mechanism causing neutropenia after
danusertib treatment is unclear and could be associated
with peak values (Cmax) or threshold values. Based on the
new pharmacogenetic data from our current analysis no
predisposition for the severity of haematological toxicity
could be identified.
Clearly, this study has its limitations. As described
earlier, due to the phase I and II nature of the studies
patient numbers were limited and the group is quite
heterogeneous. The power to find statistical significant
differences in genotype of haplotype analyses was
limited.
That clear correlations between the main enzymes and
transporters involved in danusertib metabolism, and phar-
macokinetics and toxicity are absent, does not mean that
these results are unimportant. This study outcome makes
the chance that danusertib is highly susceptible to pharma-
cogenetic variation less probable. More discrete differences,
based on pharmacogenetic variability, should be explored
further in additional (population based) pharmacogenetic
studies for this compound [34–36]. The relatively high
inter-individual variation observed could not be explained
through pharmacogenetics and, for instance, the role of
environmental factors might be important.
The reason for a lack of association between histone H3
phosphorylation and the studied AURKB polymorphism is
unclear. Whether the 893G>A mutation results in altered
gene function is unknown.
Since danusertib is currently used in two treatment
schedules, 330 mg/m
2 on days 1, 8 and 15 every 4 weeks
and 500 mg/m
2 on days 1 and 15 every 4 weeks, a population
based pharmacokinetic-pharmacogenetic model might help in
selecting the optimal treatment schedule [36–38]. A second
advantage of a population based pharmacokinetic-
pharmacogenetic model is that the relative impact of all
individual SNPs as covariates can be explored.
In conclusion, in this explorative study no significant
associationsbetweenpolymorphismsingenescodingfordrug
metabolizing enzyme, for transporter proteins and clearance
of danusertib, between target receptor polymorphisms and
toxicity of danusertib and between polymorphisms in the
aurora kinase B receptor and the extent of histone H3
phosphorylation wereseen. Futurestudies,including analyses
of more patients on danusertib treatment and the use of
population based pharmacokinetic-pharmacogenetic models
to select the optimal danusertib treatment schedule are
planned.
Gene SNPS Haplotype Neutropenia grade 3-4 p-value
KDR −604T>C TCT 0.146
1192G>A CCT 0.460
1719A>T CCA 1.000
RET 37412G>A GG 0.773
135G>A GA 0.773
AURKA 169G>A GA 0.205
91A>T AA 0.672
GT 0.110
Gene SNPS Haplotype p-value clearance L/hour/m
2 d1c1
ABCB1 1236C>T GCC 0.953
2677G>A/T TTT 0.935
3435C>T
ABCG2 15994G>A CC 0.859
1143C>T TT 0.588
FMO3 15167G>A AGA 0.537
21443A>G GGG 0.603
18281G>A GAC 0.017
Table 5 Haplotype analysis:
uncorrected P values using
Pearson X
2 analysis, indepen-
dent samples t-test or
one-way ANOVA where
appropriate
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